Art

J-GLOBAL ID：201802229110736484   Reference number：18A1141189

Chimeric antigen receptor T cells: a novel therapy for solid tumors

キメラ抗原受容体T細胞:固形腫瘍の新規治療法【JST・京大機械翻訳】

Author (7)： Yu Shengnan (Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Li Anping (Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China) ,  Liu Qian (Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Li Tengfei (Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China) ,  Yuan Xun (Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Han Xinwei (Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China) ,  Wu Kongming (Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
Material： Journal of Hematology & Oncology (Web)
Volume： 10  Issue： 1  Page： 78  Publication year： 2017 
JST Material Number： U7517A  ISSN： 1756-8722  Document type： Article
Article type： 文献レビュー  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： The chimeric antigen receptor ...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1141189&from=J-GLOBAL&jstjournalNo=U7517A") }}

Thesaurus term： *T cell ,  cytotoxicity ,  *tumor ,  human(primates) ,  literature review ,  tumor cell ,  cell transplantation ,  EGF receptor ,  metabasis ,  mesothelioma ,  *antigen ,  clinical trial ,  *solid tumor ,  interaction
Semi thesaurus term： *キメラ抗原受容体 , 【Automatic Indexing@JST】

Author keywords (5)： CAR-T cell ,  EGFR ,  HER2 ,  Mesothelin ,  Solid tumors

JST classification (1)： Immunotherapy for tumors  (GE03035B)

Reference (146)：

• Adv Cancer Res; The new era of cancer immunotherapy: manipulating T-cell activity to overcome malignancy; DN Khalil, S Budhu, B Gasmi, R Zappasodi, D Hirschhorn-Cymerman, T Plitt; 128; 2015; 1-68; 10.1016/bs.acr.2015.04.010; CR1;
• Nature; Cancer immunotherapy comes of age; I Mellman, G Coukos, G Dranoff; 480; 7378; 2011; 480-489; 10.1038/nature10673; CR2;
• Maher J, Wilkie S, Davies DM, Arif S, Picco G, Julien S, Foster J, Burchell J, Taylor-Papadimitriou J. Targeting of Tumor-Associated Glycoforms of MUC1 with CAR T Cells. Immunity. 2016;45(5):945-946.
• Immunol Rev; Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma; M Chmielewski, AA Hombach, H Abken; 257; 1; 2014; 83-90; 10.1111/imr.12125; CR4;
• Nat Rev Cancer; Engineered T cells: the promise and challenges of cancer immunotherapy; AD Fesnak, CH June, BL Levine; 16; 9; 2016; 566-581; 10.1038/nrc.2016.97; CR5;

Terms in the title (4)： キメラ抗原受容体 ,  T細胞 ,  固形腫瘍 ,  治療法